Publications by authors named "Markqayne D Ray"

Claim this Profile
V
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.
Miguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, Markqayne D Ray, Yael A Rodriguez-Guadarrama

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.
Frederick L Locke, Graeme Ball, Markqayne D Ray, Tony Li, Eve H Limbrick-Oldfield

Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis.
Olalekan O Oluwole, Markqayne D Ray, Hanxiao Ma, Rishika Sharma, Anik R Patel

Transplant Cell Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.
Eve H Limbrick-Oldfield, Steve Kanters, Markqayne D Ray, Timothy Best, Madhu Palivela

EJHaem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma.
Markqayne D Ray, Steve Kanters, Sara Beygi, Timothy Best, Jacob Wulff

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States.
Olalekan O Oluwole, Markqayne D Ray, Katherine L Rosettie, Graeme Ball, Jorge Jacob

Value Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade

Expert Rev Anticancer Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
Olalekan O Oluwole, Markqayne D Ray, Richard M Zur, Cheryl P Ferrufino, Brett Doble

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Jessica Owen

Clin Lymphoma Myeloma Leuk· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Olalekan O Oluwole, Markqayne D Ray, Neil Davies, Rory Bradford, Calum Jones

J Med Econ· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
M Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Markqayne D Ray

Expert Rev Anticancer Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis